Search

Your search keyword '"van Opbergen, C J M"' showing total 7 results
Start Over Author "van Opbergen, C J M"
7 results on '"van Opbergen, C J M"'

4. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

Author

Kamel, S M, van Opbergen, C J M, Koopman, C D, Verkerk, A O, Boukens, B J D, de Jonge, B, Onderwater, Y L, van Alebeek, E, Chocron, S, Polidoro Pontalti, C, Weuring, W J, Vos, M A, de Boer, T P, van Veen, T A B, Bakkers, J, Kamel, S M, van Opbergen, C J M, Koopman, C D, Verkerk, A O, Boukens, B J D, de Jonge, B, Onderwater, Y L, van Alebeek, E, Chocron, S, Polidoro Pontalti, C, Weuring, W J, Vos, M A, de Boer, T P, van Veen, T A B, and Bakkers, J

Abstract

The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca2+ level, slower Ca2+ transient decay and longer Ca2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.

Published
2021

5. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

Author

Hubrecht Institute with UMC, Conductiegroep, Medische Fysiologie, Genetica Groep Koeleman, Cancer, Circulatory Health, Child Health, Kamel, S M, van Opbergen, C J M, Koopman, C D, Verkerk, A O, Boukens, B J D, de Jonge, B, Onderwater, Y L, van Alebeek, E, Chocron, S, Polidoro Pontalti, C, Weuring, W J, Vos, M A, de Boer, T P, van Veen, T A B, Bakkers, J, Hubrecht Institute with UMC, Conductiegroep, Medische Fysiologie, Genetica Groep Koeleman, Cancer, Circulatory Health, Child Health, Kamel, S M, van Opbergen, C J M, Koopman, C D, Verkerk, A O, Boukens, B J D, de Jonge, B, Onderwater, Y L, van Alebeek, E, Chocron, S, Polidoro Pontalti, C, Weuring, W J, Vos, M A, de Boer, T P, van Veen, T A B, and Bakkers, J

Published
2021

7. Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy

Author

Paul M.L. Janssen, Jeff S. Healey, Nara Sobriera, Hugh Calkins, Samantha L. Simmons, Sharon L. Graw, Peter J. Mohler, Mona El-Refaey, Robert W. Davies, Brittney Murray, Danna A. Spears, Kirti Mittal, Duy T. Nguyen, Jason D. Roberts, Crystal Tichnell, Maarten P. van den Berg, J. Peter van Tintelen, Nathaniel P. Murphy, Sara N. Koenig, Daniel P. Judge, Philip C. Ursell, Meriam Åström Aneq, Mei Han, Crystal F. Kline, Robert A. Hegele, Anna Gréen, Luisa Mestroni, Andrew D. Krahn, Robert M. Hamilton, Amy C. Sturm, Arthur A.M. Wilde, Babak Nazer, Frank I. Marcus, Gianfranco Sinagra, Michael H. Gollob, Alberto Codima, David A. Chiasson, Chantal J. M. van Opbergen, Matthew R.G. Taylor, Shabana Aafaqi, Cynthia A. James, Edgar T. Hoorntje, Martin J. Gardner, Tamara T. Koopmann, Ellen R. Lubbers, Meena Fatah, Anthony Tang, Hassan Musa, Muhammad Rafiq, Loren E. Wold, Allan C. Skanes, Thomas J. Hund, John F. Robinson, Melvin M. Scheinman, Elisabeth M. Lodder, Toon A.B. van Veen, Roberts, J. D., Murphy, N. P., Hamilton, R. M., Lubbers, E. R., James, C. A., Kline, C. F., Gollob, M. H., Krahn, A. D., Sturm, A. C., Musa, H., El-Refaey, M., Koenig, S., Aneq, M. A., Hoorntje, E. T., Graw, S. L., Davies, R. W., Rafiq, M. A., Koopmann, T. T., Aafaqi, S., Fatah, M., Chiasson, D. A., Taylor, M. R. G., Simmons, S. L., Han, M., Van Opbergen, C. J. M., Wold, L. E., Sinagra, G., Mittal, K., Tichnell, C., Murray, B., Codima, A., Nazer, B., Nguyen, D. T., Marcus, F. I., Sobriera, N., Lodder, E. M., Van Den Berg, M. P., Spears, D. A., Robinson, J. F., Ursell, P. C., Green, A. K., Skanes, A. C., Tang, A. S., Gardner, M. J., Hegele, R. A., Van Veen, T. A. B., Wilde, A. A. M., Healey, J. S., Janssen, P. M. L., Mestroni, L., Van Tintelen, J. P., Calkins, H., Judge, D. P., Hund, T. J., Scheinman, M. M., Mohler, P. J., Cardiovascular Centre (CVC), Cardiology, Human Genetics, and ACS - Heart failure & arrhythmias

Subjects
Male, 0301 basic medicine, Indoles, Cardiac fibrosis, Cell- och molekylärbiologi, Cardiomyopathy, Arrhythmias, Cardiovascular, Medical and Health Sciences, Sudden cardiac death, Maleimides, Mice, 0302 clinical medicine, 2.1 Biological and endogenous factors, Aetiology, Wnt Signaling Pathway, Arrhythmogenic Right Ventricular Dysplasia, beta Catenin, Mice, Knockout, Ejection fraction, Cardiology, Cardiovascular disease, Cell Biology, Genetic diseases, Wnt signaling pathway, General Medicine, Phenotype, 3. Good health, Heart Disease, 030220 oncology & carcinogenesis, Female, Arrhythmia, Research Article, Ankyrins, Knockout, Immunology, 03 medical and health sciences, Rare Diseases, Clinical Research, ANK2, Journal Article, medicine, Animals, Humans, Loss function, Animal, business.industry, Myocardium, medicine.disease, Disease Models, Animal, 030104 developmental biology, Disease Models, Cancer research, business, Cell and Molecular Biology
Abstract

Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia syndrome characterized by severe structural and electrical cardiac phenotypes, including myocardial fibrofatty replacement and sudden cardiac death. Clinical management of ACM is largely palliative, owing to an absence of therapies that target its underlying pathophysiology, which stems partially from our limited insight into the condition. Following identification of deceased ACM probands possessing ANK2 rare variants and evidence of ankyrin-B loss of function on cardiac tissue analysis, an ANK2 mouse model was found to develop dramatic structural abnormalities reflective of human ACM, including biventricular dilation, reduced ejection fraction, cardiac fibrosis, and premature death. Desmosomal structure and function appeared preserved in diseased human and murine specimens in the presence of markedly abnormal beta-catenin expression and patterning, leading to identification of a previously unknown interaction between ankyrin-B and beta-catenin. A pharmacological activator of the WNT/beta-catenin pathway, SB-216763, successfully prevented and partially reversed the murine ACM phenotypes. Our findings introduce what we believe to be a new pathway for ACM, a role of ankyrin-B in cardiac structure and signaling, a molecular link between ankyrin-B and beta-catenin, and evidence for targeted activation of the WNT/beta-catenin pathway as a potential treatment for this disease. Funding Agencies|Marianne Barrie Philanthropic Fund; Canadian Institutes of Health Research [RN332805]; Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organisation for Health Research and Development; Royal Netherlands Academy of Sciences [CVON-PREDICT 2012-10]; Netherlands Cardiovascular Research Initiative - Dutch Heart Foundation [CVON2012-10 PREDICT CVON2018-30 PREDICT2, CVON2015-12 eDETECT]; Netherlands Organization for Scientific Research (NWO) [040.11.586]; Fondation Leducq [16 CVD 02]; Dr. Francis P. Chiramonte Private Foundation; Leyla Erkan Family Fund for ARVD Research; Robin Shah ARVD Fund at Johns Hopkins; Bogle Foundation; Healing Hearts Foundation; Campanella Family; Patrick J. Harrison Family; Peter French Memorial Foundation; Wilmerding Endowments; NIH [HL135754, HL134824, HL139348, HL135096, HL114383, HL114893, HL137331, HL137325, 2UM1HG006542, UL1 TR 001079]; Ohio State Frick Center; JB Project

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results